
GOVERNMENT NOTICE

DEPARTMENT OF HEALTH

NO.....

.....2023


MEDICINES AND RELATED SUBSTANCES ACT, (ACT NO. 101 OF 1965)

ANNUAL SINGLE EXIT PRICE ADJUSTMENT [SEPA] OF MEDICINES AND SCHEDULED SUBSTANCES FOR THE YEAR 2024

I, DR MJ PHAAHLA, the Minister of Health, has determined on recommendation of the Pricing Committee, in terms of Regulation 8(1) of the Regulations relating to a Transparent Pricing System for Medicines and Scheduled Substances published in terms of the Medicines and Related Substances Act, (Act 101 of 1965), that the Single Exit Price (SEP) of Medicines and Scheduled Substances may be adjusted by not greater than **6.79%** of the SEP of medicines and their related pack sizes that was available as at 20th December 2023 regardless of how that SEP was arrived at in the 2021 cycle. Applications for adjustments of the SEP may only be submitted for the first time in 2024 from 12th January 2024 and by no later than 08th March 2024.

All medicines and their related pack sizes with SEP approved with an effective date later than 20th December 2023 are not eligible for SEPA 2024. An applicant may only submit once in the 2024 cycle unless a re-submission is made for eligible medicines that have not been previously approved for an adjustment in the 2024 period in which an application was made. The final date for re-submissions will be 25th March 2024. Applicants with any other type of SEP-related submission in the system must either wait for the finalization of such a submission before lodging the SEPA 2024 submission or withdraw the submission within the system before the SEPA 2024 submission is lodged. The lodgment of a SEPA 2024 submission shall automatically terminate the processing of any SEP-related submission already in the system.

An adjustment in the Single Exit Price in terms of this Notice may only be implemented by the manufacturer or importer of the relevant medicine or scheduled substance, no later than 32 working days after the date that the manufacturer or importer has communicated the information requested by the Director-General in terms of the Notice published in terms of Regulation 21 of the Regulations Relating to a Transparent Pricing System for medicines and scheduled substances.


DR MJ PHAAHLA, MP
MINISTER OF HEALTH

DATE: 11/01/2024